Update on Therapeutic Options for Helicobacter pylori-related Diseases.
Triple therapy including clarithromycin, amoxicillin, and a proton pump inhibitor (PPI) has been recommended as the treatment of choice for Helicobacter pylori eradication. This regimen is now challenged by an increasing level of clarithromycin resistance that jeopardizes the treatment success. When clarithromycin resistance has been detected, or when its rate is known to be high in the geographic area, this drug cannot be used. It can be replaced by metronidazole, the resistance of which has a limited clinical relevance. Another option is to prescribe tetracycline and metronidazole with a PPI or ranitidine bismuth citrate. New antibiotics such as levofloxacin or rifabutin can also be used in combination with amoxicillin and a PPI. Probiotics can be added to all of these regimens to improve compliance by decreasing adverse events. But some authors advocate a quadruple therapy as a first-line treatment. Solutions to improve the limitations of this last regimen are now being proposed. Clarification of the controversial treatment indications such as gastroesophageal reflux disease or prevention of nonsteroidal anti-inflammatory drug gastroduodenal symptoms has been made. The question of prevention of gastric carcinoma by H. pylori eradication remains unanswered.
Mégraud
Francis
F
Laboratoire de Bactériologie, Hôpital Pellegrin, 33076 Bordeaux Cedex, France. francis.megraud@chu-bordeaux.fr.
Gastroenterol Clin Biol. 2002 Mar;26(3):216-9
11981460
Dig Liver Dis. 2004 Jun;36(6):384-7
15248377
World J Gastroenterol. 2004 Jun 1;10(11):1656-8
15162544
Am J Gastroenterol. 2004 Sep;99(9):1833-55
15330927
Aliment Pharmacol Ther. 2003 Sep 15;18(6):647-54
12969092
Aliment Pharmacol Ther. 2000 May;14(5):603-9
10792124
Aliment Pharmacol Ther. 2004 Feb 1;19(3):253-61
14984371
Clin Gastroenterol Hepatol. 2004 Nov;2(11):997-1002
15551252
Aliment Pharmacol Ther. 2003 Jan;17(1):99-109
12492738
J Gastroenterol Hepatol. 2003 Jul;18(7):778-82
12795748
Can J Gastroenterol. 2003 Jun;17 Suppl B:36B-40B
12845349
Aliment Pharmacol Ther. 2002 Apr;16(4):793-8
11929398
Gut. 2004 Sep;53(9):1374-84
15306603
JAMA. 2004 Jan 14;291(2):187-94
14722144
J Clin Microbiol. 2003 Jan;41(1):397-402
12517879
Aliment Pharmacol Ther. 2004 Nov 15;20(10):1071-82
15569109
J Antimicrob Chemother. 2001 May;47(5):709-10
11328791
Aliment Pharmacol Ther. 2003 Oct 15;18(8):791-7
14535872
Can J Gastroenterol. 1999 Apr;13(3):213-7
10331931
Aliment Pharmacol Ther. 2003 Jun 15;17(12):1545-51
12823158
Aliment Pharmacol Ther. 2000 Dec;14(12):1639-43
11121913
Aliment Pharmacol Ther. 2004 Nov 15;20(10):1181-8
15569121
J Gastroenterol. 2004 Nov;39(11):1051-5
15580397
Am J Gastroenterol. 2003 Mar;98(3):562-7
12650788
Aliment Pharmacol Ther. 2004 Feb;19 Suppl 1:9-16
14725573
Gut. 2004 Feb;53(2):312-3
14724171
Aliment Pharmacol Ther. 2002 Feb;16(2):167-80
11860399
Aliment Pharmacol Ther. 2003 Feb;17(3):415-20
12562455
Helicobacter. 1999 Jun;4(2):106-12
10382124
Am J Med. 2004 Sep 6;117 Suppl 5A:86S-91S
15478858
Aliment Pharmacol Ther. 2003 Jun 1;17(11):1333-43
12786627
Aliment Pharmacol Ther. 2000 Oct;14(10):1339-43
11012480
Am J Gastroenterol. 2000 Nov;95(11):3317-8
11095372
Aliment Pharmacol Ther. 2000 Mar;14(3):311-6
10735924
J Clin Gastroenterol. 2000 Oct;31(3):222-5
11034001
J Gastroenterol Hepatol. 1998 Jan;13(1):1-12
9737564
Lancet. 1984 Jun 16;1(8390):1311-5
6145023
Gut. 1997 Jul;41(1):8-13
9274464
Eur J Gastroenterol Hepatol. 2004 Oct;16(10):987-90
15371921
Am J Gastroenterol. 2000 Oct;95(10):2688-91
11051336
J Clin Microbiol. 2004 Oct;42(10):4512-8
15472302
Clin Gastroenterol Hepatol. 2003 Jul;1(4):273-8
15017668
Helicobacter. 2003 Apr;8(2):90-4
12662375
Aliment Pharmacol Ther. 2003 Oct 15;18(8):821-7
14535876
Helicobacter. 2004 Apr;9(2):124-9
15068413
J Antimicrob Chemother. 2000 Dec;46(6):1029-31
11102427